Cefotaxime sodium did not burst onto the scene out of nowhere. It came to light in the 1970s, crafted as a response to growing worries about drug-resistant bacterial infections. Back then, doctors were watching older antibiotics lose their punch as bacteria learned to fight back. Scientists in Japan looked to the cephalosporin molecule for answers, hoping a tweak here or there might give medicine an edge again. Their research led to cefotaxime, a compound strong enough to take on a diamond-hard crowd of Gram-negative bacteria. The sodium salt form let it dissolve easily for shots and drips, so hospitals everywhere latched onto it. Through decades, it stuck around because doctors saw time and again that it helped turn the tide in tough infections, even as bacteria kept trying to outsmart the arsenal.
Cefotaxime sodium sells as a white or off-white powder, usually for mixing with water before injection. Companies pack it in glass vials, sealed to keep out moisture and air. This salt of cefotaxime lets doctors fight off severe infections caused by bacteria that laugh at weaker antibiotics. These days, you see it in ERs and wards dealing with pneumonia, septicemia, bone infections, skin wounds, and more. Folks on the inside of hospital medicine know its power, especially where treatment has to start fast and the bug in question keeps changing. It still lines pharmacy shelves because it works where older drugs stumble, tackling serious infections that could go downhill in a hurry.
Cefotaxime sodium belongs to the cephalosporin group, derived from a mold called Acremonium. Its chemical structure packs a beta-lactam ring—nature’s bulldozer against bacteria. In plain water, it dissolves easily, which makes mixing for injection a straight shot in wards or clinics. Under normal light, the powder stays stable, but heat or dampness can break it down and sap its strength. In tests, it shows melting points in the range above 160°C, which matches what chemists expect from a strong molecule with several rings and side chains stacked together. Its formula, C16H16N5NaO7S2, fits into pharmacology’s understanding of how antibiotics must look to wreak havoc among bacteria. The shape and charge help it slip through bacterial walls to reach the hunting grounds where it stops cell wall building.
Every batch of cefotaxime sodium rolls out with details on purity, dosage, and handling. Labels show the batch number, expiration date, storage suggestions, and the weight of active drug—usually with vials marked for 500 mg or 1 g doses. There are warnings about keeping the powder dry and at room temperature to keep it from losing punch before use. Technical sheets included with pharmacy orders spell out the pH range after mixing (about 4.5-6.5) and make it clear how to mix for injections or intravenous drips. Traceability and instructions are not an afterthought; nurses and doctors count on those lines to keep mistakes off the ward.
In the lab, chemists start with cephalosporin C fermentation by certain molds, which lays down the backbone for cefotaxime. This raw material takes a chemical route, where modifications add side chains to upgrade its bacteria-killing skills. Specific solvents and catalysts help with the addition of the syn-oxime methyl group and the aminothiazolyl side chain. These tweaks arm cefotaxime to resist beta-lactamases—enzymes spit out by germs to chew up ordinary antibiotics. The result runs through purification, crystallization, and finally dries as a sodium salt that dissolves for easy use in a hospital. Each batch faces testing for unwanted leftovers and purity, so only clean, strong powder reaches doctors.
The heart of cefotaxime’s fight against bacteria sits in its beta-lactam ring and oxyimino side chains. These features let it slip past many resistance tricks bacteria fashion, so it holds its ground where earlier cephalosporins fail. Chemists have tinkered with its structure, leading to related compounds like ceftriaxone and ceftazidime—each tweaked for stronger results, broader reach, or fewer side effects. Reactions to tinker with the molecule need tight control, since the beta-lactam ring can break open if the process runs too long or gets too hot. Once inside the body, cefotaxime can stay strong even in the shadow of penicillinases—one key reason it remains a go-to drug for tough hospital infections.
Cefotaxime sodium appears on pharmacy stock lists under many names. Physicians or pharmacists might spot it as Claforan, used in high-traffic wards around the world. In scientific circles, it goes by its chemical handle: sodium (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Other listings drop simpler labels such as cefotaxime sodium powder or sodium cefotaxime. No matter the name, the powder in the vial comes from the same roots—and brings the same power.
Hospitals track antibiotic use closely, and cefotaxime sodium sits on that list. Handling the powder means wearing gloves, covering open wounds, and sticking to standard precautions—since even a stray whiff could set off allergies for some staff. The powder must be mixed just before use, with single-use vials to dodge contamination that could endanger patients. Staff must be ready for sudden allergic reactions, especially among people with a history of penicillin trouble. Waste, spills, and leftover doses follow hospital policy, making sure none trickle into water systems where half-used antibiotics could breed superbugs in the wild. These routines don’t bend, because one mistake can lead to a world of pain for patients and the broader fight against drug resistance.
Doctors reach for cefotaxime sodium when infection sets in fast and complications start stacking up. It's saved lives in cases of pneumonia, sepsis, meningitis, bone and joint infections, skin wounds, and even post-surgical fevers. Pediatricians trust this antibiotic to cross the blood-brain barrier—a must for infants and children with meningitis. Its punch in fighting bacteria that survive early antibiotics explains its place on hospital crash carts everywhere. Surgeons choose it for complicated wounds, and intensive care staff count on it when every minute matters in overwhelming infections. These days, it still gets the nod in guidelines for treating infections caused by multi-resistant bugs, especially where doctors suspect a Gram-negative culprit.
Work on cefotaxime sodium keeps rolling forward. Scientists still study the rise of resistance genes that try to block this drug, hoping to find out which pathogens are learning new tricks. Molecular research digs into how its unique side chain structure blocks enzymes like beta-lactamases. In the hunt for the next line of defense, new studies try out combinations—mixing cefotaxime with other drugs or inhibitors—to target stubborn bacteria. Research has also focused on refining dosing in specific populations such as preterm infants, older folks, or patients with kidney trouble. Every technical advance grows out of this hands-on lab and clinical work, searching for ways to stretch the drug's power or target it more carefully, aiming for fewer side effects with stronger targeting of disease.
Cefotaxime sodium has a solid safety track record. Still, nothing in medicine comes free from risk. Researchers keep tabs on toxic effects, collecting reports of allergy, gut disturbance, kidney effects, or shifts in blood counts. In rare cases, very high doses or prolonged courses can nudge the body toward trouble: skin rashes, swelling, diarrhea, or changes in white blood cell counts. Animal studies show that the risks sit much lower than in many old-style antibiotics. Careful dosing and regular checks are baked into treatment plans. Since some patients don't clear drugs quickly—like those with kidney or liver trouble—clinicians make choices based on real data and personalized monitoring. Each dose, each course, rides on a heap of research about benefits and risks, all tracking back to careful observation in labs and patient wards.
The world needs weapons against bacteria that learn too quickly for comfort. As resistance grows, doctors turn to drugs that have proven they can put up a fight under heavy pressure. Cefotaxime sodium doesn't just hang onto a spot in treatment—it points the way for next-generation antibiotics. In coming years, blending it with new enzyme blockers or delivery systems may help push back against infections that stare down whole drug cabinets. The push to conserve its power means hospital pharmacists run tight controls and stewardship programs, watching every dose. All the while, university chemists and clinical trial teams keep coming up with tweaks to extend its time in the field. As old diseases stage comebacks or new ones break out, cefotaxime sodium will stand as a trusted part of the antibiotic line-up, shaped by lessons learned in decades of hard-won experience.
Folks hear the term “Cefotaxime Sodium” and probably think it belongs in a science textbook. In reality, this medicine plays a big role in keeping people out of hospital beds for too long. Doctors and nurses go for this antibiotic when they deal with infections that won’t just back down on their own. Issues like severe pneumonia, meningitis, bone infections, or even infections after surgery show up, and standard medicines fall short. Here’s where Cefotaxime Sodium comes into play — it goes deep, reaching areas of the body where other drugs struggle.
I remember one winter, my neighbor caught a nasty case of bacterial pneumonia. Over-the-counter cold remedies weren’t helping a bit. After a hospital visit, doctors hooked him up to an IV carrying Cefotaxime Sodium. He started to breathe easier after a few doses, and that quick turnaround saved him a trip to the ICU.
Cefotaxime Sodium is part of the cephalosporin family. This group of antibiotics takes down bacteria by targeting their protective cell walls. A bacterium without a proper wall can’t survive. What’s remarkable about Cefotaxime is how well it fights off tough bacteria — those that keep changing their tricks and couldn’t care less about older drugs like penicillin. Hospitals appreciate Cefotaxime because it covers a wide range of bacteria, including notorious troublemakers such as Streptococcus pneumoniae, Haemophilus influenzae, and certain strains of E. coli. This makes it a solid pick for someone facing an emergency bacterial infection.
Hospital infections bring a heavy risk for patients recovering from surgery or dealing with weak immune systems. Cefotaxime Sodium, given through a drip or injection, steps in fast and starts working throughout the bloodstream. Children, adults, and even fragile seniors can receive doses that match their weight and condition. Doctors rely on lab tests that show exactly which bacteria are causing harm, then pull out Cefotaxime if it has a proven track record against the culprit.
All antibiotics, including Cefotaxime, risk losing their punch if overused or misused. I’ve seen stories where somebody demands antibiotics for every cough or sniffle, not knowing that overuse gives bacteria a chance to evolve and learn new defenses. Responsible prescribing stays crucial. According to studies published in The Lancet and research from the CDC, antibiotic resistance causes millions of people worldwide to end up with infections that no medicine can cure. By focusing drugs like Cefotaxime on the cases that genuinely need it—serious infections identified by proper testing—doctors help protect this valuable tool for future patients.
People ask what makes Cefotaxime special, and I’d say it’s the trust built through real-world results. That trust holds as long as clinicians respect the medicine, patients follow complete courses, and researchers keep an eye on resistance trends. Hospitals can adopt strict prescribing rules, and public health educators can reach out with clear explanations. Families can play their part by understanding that not every fever calls for antibiotics. Each action adds up, keeping Cefotaxime ready to work when someone truly needs it most.
Many people find themselves confused about antibiotics, especially those given in hospitals. Cefotaxime sodium ranks as a workhorse among injectables. In my experience talking with frontline nurses and watching busy hospital units, this isn’t just medicine carried in a little glass bottle—it’s a lifeline for people battling tough infections. Most folks never see the behind-the-scenes care that goes into every shot or drip, but this routine shapes outcomes for thousands each day.
Doctors use cefotaxime sodium through two main routes: intravenous (IV) and intramuscular (IM) injections. Let’s lay it out. Some infections need this antibiotic to kick in fast—a slow pill won’t cut it. That’s why IV feels like the gold standard, especially in emergencies or for really sick patients. The nurse prepares the powder with sterile water, draws it up, and puts it directly into the bloodstream. This blasts the infection right at its source, without any pit stop in the stomach.
For folks who can’t handle an IV, or sometimes in rural clinics without fancy setups, IM comes into play. The nurse mixes and injects it deep into a big muscle—usually the hip or thigh. Absorption runs a bit slower compared to IV, and a tough IM shot sometimes stings. I’ve watched patients flinch, but still thank the team for relief after a bad infection wouldn’t let them sleep all night.
Sticking to the right route holds real weight. You don’t want to gamble with an infection that’s closing in. In my early career, I saw a child with meningitis bounce back after a rapid IV course of cefotaxime, just hours after arrival in the ER. If a dose goes in too slow or through the wrong route, bacteria can regroup, raising the chance of life-threatening problems. Dosing by vein gives control over the amount and speed, so tough bacteria don’t stand a chance.
Hospitals struggle with tight schedules and staff shortages. Nurses juggle many patients, yet every dose still needs exactness—mixing, measuring, labeling. Once, a colleague nearly gave a wrong dose in the rush of night shift. These mistakes aren’t rare, and every slip can put a patient at risk for side effects or make the infection worse.
Part of the solution lies in better training. Regular refreshers on preparation, plus double-checks built into routines, make a big difference. Digitized medication tracking helps too. Automated alerts flag errors in dosage. I’ve met pharmacists working round the clock during outbreaks, triple-checking orders and relaying tips to nurses, because teamwork plugs the gaps where the system stumbles.
People in remote areas sometimes face delays. Rural clinics might run short on supply, or lack the right equipment to safely start an IV. Outreach programs that deliver antibiotics and teach simple but safe techniques save lives. I remember a community nurse who learned how to give IM injections through a WhatsApp group with distant doctors. That initiative boosted survival for kids with severe pneumonia, even miles from a formal hospital.
Every step in giving cefotaxime sodium—mixing, measuring, deciding on IV or IM, checking patient records—carries weight that most never see. It’s not just about fighting infection. It’s about delivering careful, respectful care, one dose at a time. For many, that’s the difference between hope and heartbreak.
Cefotaxime sodium has saved more than a few folks from tough bacterial infections. Hospitals keep it on hand for its power against pneumonia, urinary tract infections, sepsis, meningitis, and other serious conditions. Even so, doctors and nurses, myself included, have witnessed patients experience side effects, reminding us that strong medicine always brings some baggage. Knowing what to expect and talking openly about these risks builds trust between patients and providers.
Most antibiotics come with predictable complaints, and cefotaxime follows suit. It’s not rare to see patients deal with digestive issues. Nausea and diarrhea often crop up after a few days of treatment. Stomach pain or bloating can tag along. Some patients find these symptoms mild enough to tolerate, but others struggle with daily discomfort that interrupts their recovery. Healthcare teams see these patterns often, and it’s no surprise the Centers for Disease Control and Prevention list gastrointestinal disturbances as a top antibiotic side effect.
Allergic reactions take things to a new level of seriousness. Rashes can develop, itching spreads, and sometimes breathing becomes hard. Anyone with a known allergy to penicillins has a higher chance of reacting this way. Sometimes a patient’s description of a childhood rash gets dismissed, but any history of allergic response matters. Hospitals talk about anaphylaxis — a life-threatening rapid reaction — in every antibiotic safety briefing for good reason.
Other symptoms sneak up less often but still deserve attention. Headache and dizziness might cause someone to feel off-balance, raising fall risks, especially in hospital settings. Blood tests sometimes reveal shifts in white blood cell counts, which can signal stress on the immune system or bone marrow. Healthcare workers track these numbers, knowing antibiotics can cause dips or spikes that affect infection-fighting ability or leave patients vulnerable.
Another problem the medical field contends with is the threat of Clostridium difficile (C. diff) infection. After years spent on hospital wards, I’ve seen what happens when antibiotics disrupt the gut’s natural bacteria. C. diff overgrows, driving persistent diarrhea that lands patients in isolation. This side effect doesn’t happen every time, but older adults and people with longer hospital stays face a higher risk. Hospitals have created protocols to catch C. diff early, but the best way to avoid it always comes down to only using antibiotics when truly needed.
Prescribers and nurses bear the responsibility to warn patients. At the same time, patients need to speak up if something feels wrong. The Food and Drug Administration tracks adverse drug events and uses these reports to adjust recommendations for safer use. Better education, honest conversations, and careful monitoring lower the odds of any one person facing lasting harm.
Staying hydrated, eating probiotics, and telling healthcare teams about new symptoms—these everyday actions make a difference. Taking a medication like cefotaxime sodium isn’t just about killing bacteria, but about navigating side effects thoughtfully. Balancing treatment success with patient safety takes vigilance from everyone involved in care.
Cefotaxime sodium lands in many hospital protocols for good reason—it’s a workhorse antibiotic that tackles stubborn infections. Still, a serious risk trips up its use. Folks who have reacted badly to cephalosporin antibiotics in the past probably shouldn’t touch cefotaxime. Even those with strong penicillin allergies need extra caution. Hospitals keep a close watch for signs of hives, trouble breathing, or a racing heart, especially right after the first dose. Serious allergies to antibiotics sound rare, but in my years volunteering on hospital rounds, I saw enough anxious parents ask about rashes and breathing trouble in their kids to treat every case with respect. Urticaria or anaphylaxis after cephalosporins can get ugly fast. Clear communication between the medical team and the patient makes all the difference.
Kidney function weighs heavily in the risk equation. Cefotaxime leaves the body through the kidneys. When someone’s kidneys don’t work the way they should—maybe due to diabetes or decades of high blood pressure—the drug can build up to unsafe levels. That can spark a chain of side effects: confusion, seizures, or just feeling “out of it.” Pharmacists push physicians to check kidney labs before and during therapy for that reason. Complete medical history, including any record of long-term kidney problems, shapes the plan. Doctors sometimes start with half the usual dose or wait longer between doses, all to keep things safe.
Some drugs get along like oil and water, and cefotaxime has a handful of problem partners. Taking it with strong diuretics—water pills like furosemide—can stress the kidneys or trigger hearing troubles. Patients dealing with complicated health problems, such as heart failure or liver disease, run a steeper risk. Families juggling lots of prescriptions should remind doctors and pharmacists about every pill in the cabinet, and chart reviews by a clinical pharmacist pay off here.
Infants, especially newborns, need a different approach. Newborn livers and kidneys don’t always process drugs like adult organs do. Nurses and neonatologists fine-tune doses for body weight and organ health, since too much of the drug can harm fragile newborn brains. Pregnant women need their doctors to weigh risks and benefits. Animal studies show few risks, but every decision goes back to the mother’s health, the infection’s danger, and the best chance to fight off disease without harming the baby.
Doctors battle growing bacteria resistance every week, so using cefotaxime just for coughs or mild sniffles does more harm than good. Patients sometimes expect antibiotics to fix every ache, and education heads off trouble. In a world where superbugs threaten routine care, sticking to guidelines for antibiotic use helps everyone.
To dodge complications, the healthcare team has to stay sharp. Allergy checks start with careful questions, especially about past drugs that caused rashes or worse. Kidney and liver labs set the roadmap. Reviewing medication lists uncovers hidden drug interactions. Patients empowered to speak up about symptoms, side effects, and history transform their own care. Hospitals investing in electronic alert systems cut errors and spot risks faster. Trust between patient and provider, honest updates about symptoms, and careful charting set the gold standard for safety. No system’s perfect, but simple steps add up to a safer experience with powerful antibiotics like cefotaxime sodium.
Pregnancy and breastfeeding invite a laundry list of questions about what’s safe for both mother and child. For women facing an infection, the need for antibiotics can’t always wait. Cefotaxime sodium, a third-generation cephalosporin, often finds its way into treatment plans for tough bacterial infections. Doctors reach for it in hospitals when other antibiotics fail or can’t be used. The conversation about its safety for pregnant or breastfeeding women needs a closer look.
The Food and Drug Administration sorts medications into categories based on risk. Cefotaxime lands in pregnancy category B. Animal studies haven’t shown harm to the fetus, but these results don’t promise complete safety for humans. Real-world evidence in pregnant women remains limited. Most women, doctors, and pharmacists I’ve spoken with fall back on balancing risk and need. Infection can threaten the life of the mother and unborn child. Unchecked, something as simple as a urinary tract infection can become life-threatening. Ignoring effective treatment often brings bigger problems than the medicine itself.
Doctors make tough calls every day. Experience counts in places where hard data runs thin. My aunt, who practiced obstetrics for decades, taught me to focus on big-picture risks. She relied on the fact that cefotaxime doesn’t seem to cross the placenta in dangerous amounts. The risk for congenital abnormalities in exposed babies stays low in reports so far. Physicians check guidelines from the World Health Organization and the American College of Obstetricians and Gynecologists. Both allow cefotaxime use during pregnancy if a safer alternative isn’t an option.
After delivery, new moms still need solid answers. Small amounts of cefotaxime end up in breast milk. Studies of drug levels in breast milk show only tiny traces, which don’t harm most healthy infants. Babies born prematurely or with kidney issues may not handle cefotaxime as well. If the mother needs this antibiotic, most lactation consultants suggest monitoring the baby for yeast infections, diarrhea, or rash. Real-life stories back this up. One pharmacist I know watched her own newborn for side effects when she needed cefotaxime to fight off a stubborn infection. Her child did just fine, but she kept her doctor in the loop and made extra visits to the pediatrician.
No one should have to make these choices alone. Healthcare workers need straight answers, not vague reassurances or confusion. Honest conversations about possible side effects and why cefotaxime may be necessary help mothers make informed decisions. Plenty of resources now guide both professionals and patients, from the CDC’s guidelines to open-access journals. Yet every pregnancy plays out differently. Women need room to ask questions and push for second opinions if they feel uneasy.
Medication safety keeps evolving with new research, and antibiotic resistance puts pressure on the system. No mother should feel guilt or anxiety for needing an antibiotic. Still, careful attention to the latest studies and close monitoring protect families from unnecessary risks. Regular training for healthcare professionals, open dialogue with patients, and strong referral networks give everyone better tools to balance safety and well-being. My experience in healthcare reminds me that trust builds when we share the whole story, not just the positives or negatives. Knowledge and communication open doors to safer outcomes for mothers and children, even in uncertain territory.
| Names | |
| Preferred IUPAC name | Sodium (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Other names |
Claforan Cefotax Cefotaximina Cefotaxime Sodium Salt Cefotaxime Disodium Salt Cefotaximum Cefotaxime Sodium USP Cefotaxime Na |
| Pronunciation | /ˌsɛfəˈtæksaɪm ˈsoʊdiəm/ |
| Preferred IUPAC name | Sodium (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-acetoxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Other names |
Claforan Cefotax Cefotaxim Cefotaxime Sodium Salt CTX Cefotaximum Cefotaximin Cefotaxime sodium |
| Pronunciation | /ˌsɛfəˈtæksaɪm ˈsoʊdiəm/ |
| Identifiers | |
| CAS Number | 64485-93-4 |
| Beilstein Reference | 1717145 |
| ChEBI | CHEBI:3500 |
| ChEMBL | CHEMBL159 |
| ChemSpider | 128561 |
| DrugBank | DB00493 |
| ECHA InfoCard | 13aebf5e-ef21-4e10-9806-ebdbf1b7fdf6 |
| EC Number | 611-573-4 |
| Gmelin Reference | 84854 |
| KEGG | D07625 |
| MeSH | D015829 |
| PubChem CID | 6474092 |
| RTECS number | XT2300000 |
| UNII | 1K573W1G9E |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID6046105 |
| CAS Number | 64485-93-4 |
| Beilstein Reference | 1714105 |
| ChEBI | CHEBI:3500 |
| ChEMBL | CHEMBL1687 |
| ChemSpider | 22246 |
| DrugBank | DB00493 |
| ECHA InfoCard | 54d768b5-5ff8-40b3-ae8e-0b9c833b2a8a |
| EC Number | 61377-41-9 |
| Gmelin Reference | 26209 |
| KEGG | **D00263** |
| MeSH | D016883 |
| PubChem CID | 6916013 |
| RTECS number | TT7525000 |
| UNII | 1KWS9ZOD12 |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID8037664 |
| Properties | |
| Chemical formula | C16H16N5NaO7S2 |
| Molar mass | 477.477 g/mol |
| Appearance | White to yellowish, crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -2.48 |
| Acidity (pKa) | 2.1 |
| Basicity (pKb) | pKb: 6.4 |
| Magnetic susceptibility (χ) | Magnetic susceptibility (χ): -73.7×10⁻⁶ cm³/mol |
| Dipole moment | 1.41 D |
| Chemical formula | C16H16N5NaO7S2 |
| Molar mass | 477.48 g/mol |
| Appearance | White to yellowish crystalline powder |
| Odor | Odorless |
| Density | Density: 1.54 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -2.3 |
| Acidity (pKa) | 2.1 |
| Basicity (pKb) | 2.1 |
| Dipole moment | 4.92 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Cefotaxime Sodium is 610.9 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Cefotaxime Sodium is 489.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | J01DD01 |
| ATC code | J01DD01 |
| Hazards | |
| Main hazards | May cause an allergic skin reaction; may cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Rx;Rx only;Injection;Powder for solution;Prescription Drug;Antibiotic;Beta-lactam;Cephalosporin |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Precautionary statements: If medical advice is needed, have product container or label at hand. Keep out of reach of children. Read label before use. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Autoignition temperature | > 410°C (770°F) |
| Lethal dose or concentration | LD50 (mouse, intravenous): 8000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50 = 8000 mg/kg |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Cefotaxime Sodium: Not established |
| REL (Recommended) | 1 g/vial |
| IDLH (Immediate danger) | Not listed |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction. |
| Precautionary statements | Precautionary statements: Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children. Use only as directed by a physician. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Lethal dose or concentration | LD50 intravenous, mouse: 8000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse (IV) 5200 mg/kg |
| NIOSH | QYJ3351H1Q |
| PEL (Permissible) | Not established |
| REL (Recommended) | 1 g/vial |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Cefotaxime Cefotaxime sodium and arginine Cefotaxime hydrochloride Ceftriaxone Cefotiam Cefuroxime Cefepime |
| Related compounds |
Cefotaxime Cefotaxime hydrochloride Ceftizoxime Ceftriaxone Cefuroxime Cefazolin Cefepime |